Ustekinumab-auub

Drug Overview

In the highly specialized field of Immunology, the arrival of high-quality biosimilar medications marks a significant milestone in expanding patient access to life-changing therapies. Steqeyma is a sophisticated Biologic medication that serves as an FDA-approved biosimilar to the reference product Stelara. As a premier Immunomodulator, Steqeyma is designed to address the underlying drivers of chronic autoimmune conditions by targeting specific pathways that lead to systemic inflammation. For patients dealing with the persistent challenges of autoimmune disorders, this Targeted Therapy provides a clinically proven option to achieve and maintain remission, enhancing long-term health outcomes.

Steqeyma belongs to the therapeutic drug class known as Interleukin Inhibitors. It is a human Monoclonal Antibody that has been developed and tested to ensure it is highly similar to its reference biologic in terms of safety, purity, and potency. In the modern healthcare landscape, biosimilars like Steqeyma help lower costs for international health systems while maintaining the rigorous academic and clinical standards expected by physicians and patients alike.

• Generic Name: Ustekinumab-auub
• US Brand Name: Steqeyma
• Route of Administration: Available as an Intravenous (IV) infusion for induction and a Subcutaneous (SC) injection for maintenance.
• FDA Approval Status: FDA-approved (2024) as a biosimilar for the treatment of multiple chronic inflammatory conditions.
  
  Learn about the benefits and clinical applications of ustekinumab-auub. This Interleukin Inhibitor is an essential medical treatment for Steqeyma (Ustekinumab biosimilar). Access complete healthcare details here.

What Is It and How Does It Work? (Mechanism of Action)

To understand the efficacy of Steqeyma, one must look at the specific cytokines that drive autoimmune responses. Cytokines are signaling proteins that act as messengers between immune cells. In conditions like psoriasis or inflammatory bowel disease, the body produces an excess of two specific cytokines: Interleukin-12 (IL-12) and Interleukin-23 (IL-23). These proteins are responsible for “turning on” the inflammatory response that mistakenly attacks healthy tissues in the skin, joints, and gastrointestinal tract.

At the molecular and cellular level, Steqeyma operates through selective cytokine inhibition.

1. Targeting the p40 Subunit: Both IL-12 and IL-23 share a common protein subunit known as p40. Steqeyma is a Monoclonal Antibody engineered to bind with high affinity specifically to this p40 subunit.
2. Interruption of Receptor Binding: By latching onto the p40 subunit, the drug prevents these cytokines from binding to the IL-12Rβ1 receptor protein found on the surface of immune cells, such as T-cells and Natural Killer (NK) cells.
3. Halting the Signaling Cascade: This blockade interrupts the JAK-STAT signaling pathway interference. Without the p40 subunit binding to its receptor, the internal “command” to produce inflammation never reaches the cell’s nucleus.
4. Suppression of Th1 and Th17 Cells: Specifically, Steqeyma prevents the activation of Th1 and Th17 cells. Th1 cells are linked to the production of Interferon-gamma, while Th17 cells produce IL-17. By suppressing these cells, Steqeyma effectively stops the “overdrive” of the immune system that leads to tissue damage and the rapid skin cell turnover characteristic of psoriasis.
5. Selective Impact: Because it targets the p40 subunit specifically, it provides a Targeted Therapy that calms the overactive parts of the immune system without causing broad, non-specific suppression of all immune functions.

FDA-Approved Clinical Indications

Steqeyma is utilized as a powerful Immunomodulator across several key indications within the Immunology spectrum.

Primary Indication

• Steqeyma (Ustekinumab biosimilar): Specifically indicated for the treatment of patients with moderately to severely active Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis.

Other Approved & Off-Label Uses

• Plaque Psoriasis (Ps): Approved for adult and pediatric patients (6 years and older) who are candidates for systemic therapy or phototherapy.
• Psoriatic Arthritis (PsA): Indicated for adult patients, either alone or in combination with methotrexate.
• Crohn’s Disease (CD): Indicated for adults with moderately to severely active disease.
• Ulcerative Colitis (UC): Indicated for adults with moderately to severely active disease.
• Off-Label Research: While not currently FDA-approved for these, similar IL-12/23 inhibitors are being studied for potential benefits in Lupus (SLE) and various forms of refractory systemic vasculitis.

Primary Immunology Indications:

• Suppression of the p40 subunit to reduce systemic inflammatory markers.
• Modulation of the Th1/Th17 axis to prevent mucosal damage in the gut.
• Regulation of keratinocyte proliferation to clear skin plaques.

Dosage and Administration Protocols

The administration of Steqeyma involves a precise protocol. For inflammatory bowel diseases, an initial IV induction dose is required to load the medication into the system, followed by subcutaneous maintenance doses.

Patient Population Adjustments:

• Weight-Based Dosing: In Crohn’s and UC, the initial IV dose is tiered (260 mg for ≤55 kg, 390 mg for 55–85 kg, and 520 mg for >85 kg).
• Pediatric Transition: For children 6 years and older with psoriasis, dosing is calculated at 0.75 mg/kg.
• Elderly: No specific dose adjustment is generally required, though monitoring for infection is critical in patients over 65.
• Missed Doses: If a dose is missed, it should be administered as soon as possible, and the original schedule should be resumed based on the new date.

Clinical Efficacy and Research Results

The clinical efficacy of Steqeyma is supported by “totality of evidence” studies conducted between 2020 and 2026. Because it is an interchangeable biosimilar, research has confirmed that switching from the reference product to Steqeyma does not lead to a decrease in efficacy or an increase in side effects.

Current clinical trial data highlights the following:

• Psoriasis Efficacy: In comparative trials, Steqeyma achieved PASI 75 (75% skin clearance) in approximately 67% to 75% of patients by week 12.
• Joint Improvement: For Psoriatic Arthritis, ACR20 and ACR50 scores showed equivalence to the reference biologic, with over 40% of patients seeing significant joint relief.
• IBD Remission: In Crohn’s and UC, precise numerical data indicates that patients using the IL-12/23 pathway inhibitors achieved clinical remission at rates exceeding 50% during the maintenance phase.
• Inflammatory Markers: Research consistently shows a significant reduction in C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) levels within the first 8 weeks of treatment. These data points confirm that the drug is efficacious in “calming” systemic inflammation at a molecular level.

Safety Profile and Side Effects

As an Immunomodulator, Steqeyma alters the immune system’s response, which necessitates a clear understanding of its safety profile.

Common Side Effects (>10%)

• Nasopharyngitis (Common cold symptoms).
• Headache and Fatigue.
• Injection site reactions (redness or itching).

Serious Adverse Events

• Serious Infections: Increased risk of bacterial, fungal, or viral infections, including the reactivation of latent Tuberculosis (TB).
• Malignancies: A theoretical risk of non-melanoma skin cancers.
• Posterior Reversible Encephalopathy Syndrome (PRES): A very rare neurological condition involving headache and visual changes.
• Hepatotoxicity: Rare instances of liver enzyme elevation.

Management Strategies

Clinical management includes mandatory screening protocols. Before the first dose, all patients must undergo a QuantiFERON-TB Gold test and Hepatitis screening. If a serious infection occurs, a “wash-out” period is required where the medication is paused. “Pre-medication” with antihistamines is rarely needed for SC injections but may be considered for the initial IV induction if a patient has a history of sensitivity.

Research Areas

Direct Clinical Connections:

Active research (2024-2026) is investigating Steqeyma’s interaction with regulatory T-cell (Treg) expansion. Scientists believe that by modulating the IL-12/23 axis, they can encourage the body to produce more Tregs, which naturally suppress autoantibody production. This could lead to longer periods of remission without the need for additional drugs.

Generalization:

The development of biosimilars like Steqeyma is a primary focus of global health brands to increase the sustainability of Immunology treatments. Research is also moving toward “Novel Delivery Systems,” such as on-body injectors and more concentrated formulas that allow for smaller injection volumes, making home-use even easier for patients with dexterity issues.

Severe Disease & Multi-Organ Involvement:

Precision Immunology research is now looking at the drug’s efficacy in preventing systemic damage, such as lupus nephritis or interstitial lung disease, in patients who have multi-organ autoimmune involvement. By using the drug earlier in the disease course, researchers hope to prevent the permanent scarring of organs.

Disclaimer: 

This information should be treated as evidence-based but not definitive. Statements implying proven Treg expansion, reliable autoantibody suppression, established on-body injector use, or guaranteed prevention of lupus nephritis and interstitial lung disease should be interpreted cautiously unless supported by direct clinical evidence. Steqeyma is an important biosimilar IL-12/23 therapy, but many broader precision-immunology and delivery-related claims remain investigational.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Complete Blood Count (CBC) and Liver Function Tests (LFTs).
• Infection Screening: QuantiFERON-TB Gold test and Hepatitis B/C screening.
• Specialized Testing: Genetic testing for enzyme deficiencies is not standard for this class, but baseline CRP and ESR are essential for tracking.
• Vaccination Review: Review of vaccination history. Patients must be up to date on all inactivated vaccines.

Monitoring and Precautions

• Vigilance: Monitoring for signs of infection, such as fever or persistent cough.
• Loss of Response: Physicians monitor for anti-drug antibodies if a patient stops responding to the Targeted Therapy.
• Lifestyle: We recommend an anti-inflammatory diet and strict sun protection to reduce the risk of photosensitivity and skin flares.

Do’s and Don’ts:

• DO report any new, persistent cough or fever to your doctor immediately.
• DO keep your Patient Safety Card with you at all times.
• DON’T receive any “live” vaccines (like shingles or MMR) while on this medication.
• DON’T miss your scheduled blood tests, as they are essential for monitoring your liver health.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Steqeyma is a potent Biologic that must only be used under the direct supervision of a qualified medical professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. In the event of a medical emergency, call your doctor or emergency services immediately.